Skip to main
ATTO

ATTO Stock Forecast & Price Target

ATTO Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Attovia Therapeutics is a biotechnology company focused on developing innovative biologics for immune-mediated diseases, with a promising product pipeline including ATTO-1310, ATTO-2306, and ATTO-1091. These drug candidates utilize the company's ATTOBODY platform, which has shown potential for optimized efficacy and convenience profiles. With a strong R&D engine and a highly validated approach, Attovia Therapeutics has the potential to capture a significant market share in the treatment of immune-related diseases.

Bears say

Attovia Therapeutics is a clinical stage biotechnology company developing biologics for immune-mediated diseases. Their comprehensive pipeline includes ATTO-1310, an antibody targeting IL-31, which has demonstrated favorable improvements in itch for chronic pruritus and atopic dermatitis, and is expected to enter Phase II trials in 2027. While their YTE half-life extension technology has been validated, the increasingly competitive landscape, potential for safety signals to emerge, and other risks pose uncertainty for their ability to finance ongoing research, garner regulatory approval, and successfully commercialize their products.

ATTO has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Attovia Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Attovia Therapeutics Inc (ATTO) Forecast

Analysts have given ATTO a Buy based on their latest research and market trends.

According to 5 analysts, ATTO has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Attovia Therapeutics Inc (ATTO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.